Modeling the Potential Role of Inactivated Poliovirus Vaccine to Manage the Risks of Oral Poliovirus Vaccine Cessation

被引:41
|
作者
Tebbens, Radboud J. Duintjer [1 ]
Thompson, Kimberly M. [1 ,2 ]
机构
[1] Kid Risk Inc, Orlando, FL 32832 USA
[2] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA
来源
基金
比尔及梅琳达.盖茨基金会;
关键词
polio; eradication; dynamic modeling; disease outbreaks; inactivated poliovirus vaccine; oral poliovirus vaccine; PARALYTIC POLIOMYELITIS; POPULATION IMMUNITY; TRANSMISSION; POLICY; IMMUNOGENICITY; SEROPREVALENCE; OUTBREAKS; CHILDREN; DISEASE; ENDGAME;
D O I
10.1093/infdis/jit838
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The Global Polio Eradication Initiative plans to stop all oral poliovirus vaccine (OPV) after wild poliovirus eradication, starting with serotype 2. Stakeholders continue to discuss the role of using inactivated poliovirus vaccine (IPV) to manage the risks of circulating vaccine-derived polioviruses (cVDPVs) during the end game. Methods.aEuro integral We use a poliovirus transmission and OPV evolution model to explore the impact of various routine immunization policies involving IPV on population immunity dynamics and the probability and magnitude of cVDPV emergences following OPV cessation. Results.aEuro integral Adding a single IPV dose to an OPV-only routine immunization schedule at or just before OPV cessation produces very limited impact on the probability of cVDPV emergences and the number of expected polio cases in settings in which we expect cVDPVs in the absence of IPV use. The highest-cost option of switching to a 3-dose IPV schedule only marginally decreases cVDPV risks. Discontinuing supplemental immunization activities while introducing IPV prior to OPV cessation leads to an increase in cVDPV risks. Conclusions.aEuro integral Introducing a dose of IPV in countries currently using OPV only for routine immunization offers protection from paralysis to successfully vaccinated recipients, but it does little to protect high-risk populations from cVDPV risks.
引用
收藏
页码:S485 / S497
页数:13
相关论文
共 50 条
  • [42] Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016
    Hampton, Lee M.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2015, 64 (25): : 699 - 702
  • [43] A mucosal adjuvant for the inactivated poliovirus vaccine
    Steil, Benjamin P.
    Jorquera, Patricia
    Westdijk, Janny
    Bakker, Wilfried A. M.
    Johnston, Robert E.
    Barro, Mario
    VACCINE, 2014, 32 (05) : 558 - 563
  • [44] Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences
    Kalkowska, Dominika A.
    Wassilak, Steven G. F.
    Wiesen, Eric
    Burns, Cara C.
    Pallansch, Mark A.
    Badizadegan, Kamran
    Thompson, Kimberly M.
    RISK ANALYSIS, 2024, 44 (02) : 366 - 378
  • [45] Addressing the inactivated poliovirus vaccine shortage
    Sutter, Roland W.
    Zaffran, Michel
    LANCET, 2019, 393 (10191): : 2569 - 2571
  • [46] COMPARISON OF ENHANCED POTENCY INACTIVATED POLIOVIRUS VACCINE (EIPV) VERSUS STANDARD ORAL POLIOVIRUS VACCINE (OPV) IN THAI INFANTS
    SIMASATHIEN, S
    MIGASENA, S
    BEUVERY, C
    VANSTEENIS, G
    SAMAKOSES, R
    PITISUTTITHAM, P
    VESIKARI, T
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1994, 26 (06) : 731 - 738
  • [47] EFFICACY OF INACTIVATED POLIOVIRUS VACCINE IN INDIA
    KRISHNAN, R
    JADHAV, M
    JOHN, TJ
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 1983, 61 (04): : 689 - 692
  • [48] INACTIVATED POLIOVIRUS VACCINE (IPV) IN NEWBORNS
    HANDSHER, R
    NEUMAN, M
    EFRAT, O
    VANWEZEL, AL
    TOROK, V
    SALK, J
    SWARTZ, TA
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1988, 24 (07): : 392 - 392
  • [49] Efficacy of inactivated poliovirus vaccine in India
    Jafari, Hamid
    Deshpande, Jagadish M.
    Sutter, Roland W.
    Bahl, Sunil
    Verma, Harish
    Ahmad, Mohammad
    Kunwar, Abhishek
    Vishwakarma, Rakesh
    Agarwal, Ashutosh
    Jain, Shilpi
    Estivariz, Concepcion
    Sethi, Raman
    Molodecky, Natalie A.
    Grassly, Nicholas C.
    Pallansch, Mark A.
    Chatterjee, Arani
    Aylward, R. Bruce
    SCIENCE, 2014, 345 (6199) : 922 - 925
  • [50] SHEDDING OF VIRULENT POLIOVIRUS REVERTANTS DURING IMMUNIZATION WITH ORAL POLIOVIRUS VACCINE AFTER PRIOR IMMUNIZATION WITH INACTIVATED POLIO VACCINE
    ABRAHAM, R
    MINOR, P
    DUNN, G
    MODLIN, JF
    OGRA, PL
    JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (05): : 1105 - 1109